M&A Deal Summary

Ginkgo Bioworks Acquires Modulus Therapeutics - Cell Therapy Assets

On April 2, 2024, Ginkgo Bioworks acquired life science company Modulus Therapeutics - Cell Therapy Assets from Modulus Therapeutics

Acquisition Highlights
  • This is Ginkgo Bioworks’ 9th transaction in the Life Science sector.
  • This is Ginkgo Bioworks’ 11th transaction in the United States.
  • This is Ginkgo Bioworks’ 1st transaction in Washington.

M&A Deal Summary
Date 2024-04-02
Target Modulus Therapeutics - Cell Therapy Assets
Sector Life Science
Buyer(s) Ginkgo Bioworks
Sellers(s) Modulus Therapeutics
Deal Type Divestiture

Target

Modulus Therapeutics - Cell Therapy Assets

Seattle, Washington, United States
Modulus Therapeutics' Cell Therapy Assets provides chimeric antigen receptor (CAR) and switch receptor libraries.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ginkgo Bioworks

Boston, Massachusetts, United States
Category Company
Founded 2008
Sector Life Science
DESCRIPTION

Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks was established in 2008 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 14 of 14
Sector (Life Science) 9 of 9
Type (Divestiture) 3 of 3
State (Washington) 1 of 1
Country (United States) 11 of 11
Year (2024) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-28 Proof Diagnostics

Cambridge, Massachusetts, United States

Proof Diagnostics is a life sciences tools, diagnostics, and computational discovery company that uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases. Proof Diagnostics was founded in 2020 and is based in Cambridge, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-10-07 AltarBio

Evry-Courcouronnes, France

AltarBio is specialized in the development of microorganisms for industrial applications. Altar's technology, which was developed in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA), automates Adaptive Laboratory Evolution and offers a unique capability to adapt microorganisms to the conditions required by industrial companies for their competitive utilization at commercial scale. AltarBio is based in Evry-Courcouronnes, France.

Sell -

Seller(S) 1

SELLER

Modulus Therapeutics

Seattle, Washington, United States
Category Company
Founded 2020
Sector Life Science
DESCRIPTION

Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. Modulus Therapeutics was formed in 2020 and is based in Seattle, Washington.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Washington) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal